Pharmaceutical giant Eli Lilly has paused late-stage clinical trials for its coronavirus antibody treatment due to safety issues.

“Safety is of the utmost importance to Lilly,” Eli Lilly spokesperson Molly McCully said in a written statement to the Washington Examiner. “We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment.”

Recommended Stories

FDA limits monoclonal antibody treatments shown to be ineffective against omicron

Pfizer says COVID-19 pill 89% effective against severe illness

Children 4 and younger will get three-dose Pfizer vaccine, Fauci says